Von Willebrand Disease (VWD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Von Willebrand Disease (VWD) Market Outlook

Thelansis’s “Von Willebrand Disease (VWD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Von Willebrand Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Von Willebrand Disease (VWD) Overview

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by phenotypic forms as follows:

1. Type 1: An autosomal dominant disease caused by a partial quantitative deficiency of von Willebrand factor (VWF), with incomplete penetrance at around 60%.
2. Type 2: An autosomal dominant disease with several qualitative defects in VWF. It has four subtypes (2A, 2B, 2N, 2M), with 2A being the most common variant.
3. Type 3: An autosomal recessive disease caused by a complete quantitative defect in VWF, resulting in undetectable levels and severe bleeding.

The VWF gene's polymorphic nature leads to various VWF levels and functions, resulting in varying disease presentations and severity. Common symptoms of VWD include frequent nosebleeds lasting over 10 minutes, prolonged bleeding from cuts or injuries, easy bruising, iron deficiency anemia, excessive bleeding after surgeries (including dental), a family history of similar symptoms, or a diagnosed bleeding disorder. Acquired von Willebrand disease occurs due to secondary processes affecting VWF function. Associated conditions include various cancers, autoimmune disorders, metabolic disorders, drug side effects, and high-flow states in the vascular system. Diagnosis relies on lab tests measuring VWF and FVIII levels, with additional tests to determine VWD type. Distinguishing acquired von Willebrand syndrome from inherited VWD can be challenging. Blood group O individuals may have slightly lower VWF levels, complicating diagnosis. Standard VWD therapy involves replacing the deficient VWF protein. Treatment options include non-replacement therapy, replacement therapy using plasma-derived concentrates like Humate-P® and Alphanate SD/HT®, and antifibrinolytics like aminocaproic acid and tranexamic acid, which inhibit fibrinolysis.

• The prevalence of VWD in the general population ranges from 0.6% to 1.3%, but symptomatic VWD requiring specific treatment is rare (approximately 1 in 10,000). Type 3 VWD is rare, occurring in approximately 1 in 1,000,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: